Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
暂无分享,去创建一个
Meric A. Ovacik | Genee Y. Lee | Amy A. Lo | Robert Piskol | P. Lupardus | L. Sun | Yan Wu | M. Das Thakur | D. Ellerman | K. Totpal | S. Chalasani | D. Leipold | C. Spiess | V. Shivva | Peiyin Wang | A. Polson | Weiyu Lin | S. Leong | L. Rougé | Michael Dillon | C. Chiu | Maria Hristopoulos | Robyn Clark | Bushra Husain | K. Z. Zimmerman Savill | Sreedevi Chalasani | Vittal Shivva | Christoph Spiess
[1] Vahan B. Indjeian,et al. Development of an ultra-sensitive human IL-33 biomarker assay for age-related macular degeneration and asthma drug development , 2021, Journal of Translational Medicine.
[2] K. H. Hoi,et al. Rapid identification of anti-idiotypic mAbs with high affinity and diverse epitopes by rabbit single B-cell sorting-culture and cloning technology , 2020, PloS one.
[3] R. Rowntree,et al. An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models , 2020, Molecular Cancer Therapeutics.
[4] Meric A. Ovacik,et al. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. , 2020, JCI insight.
[5] A. Jemal,et al. Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[6] J. Narula,et al. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers , 2020, Clinical Cancer Research.
[7] Z. Stadler,et al. Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.
[8] F. Ciardiello,et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. , 2019, Cancer treatment reviews.
[9] D. Ellerman. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. , 2019, Methods.
[10] L. Cerulo,et al. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer , 2019, Journal of experimental & clinical cancer research : CR.
[11] David J. Hermel,et al. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer , 2019, Journal of personalized medicine.
[12] P. Schnier,et al. High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies , 2018, mAbs.
[13] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[15] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[16] J. Albanell,et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). , 2017 .
[17] Thomas D. Wu,et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing , 2017, Cancer cell.
[18] Genee Y. Lee,et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. , 2017, Blood.
[19] E. Bruford,et al. Organization, evolution and functions of the human and mouse Ly6/uPAR family genes , 2016, Human Genomics.
[20] James R. Apgar,et al. Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer , 2016, Antibodies.
[21] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Diego Ellerman,et al. Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies , 2015, Science Translational Medicine.
[23] A. Ebens,et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. , 2014, Cancer research.
[24] B. Mumey,et al. Antigen-antibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. , 2012, Biochimica et biophysica acta.
[25] P. Kufer,et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen , 2010, Cancer Immunology, Immunotherapy.
[26] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[27] Carsten Reinhardt,et al. Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.
[28] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[29] Begoña Aguado,et al. Characterization of the five novel Ly‐6 superfamily members encoded in the MHC, and detection of cells expressing their potential ligands , 2006, Protein science : a publication of the Protein Society.
[30] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[31] R. Campbell,et al. Transcriptional analysis of a novel cluster of LY-6 family members in the human and mouse major histocompatibility complex: five genes with many splice forms. , 2002, Genomics.
[32] L. Simmons,et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. , 2002, Journal of immunological methods.
[33] J. Wells,et al. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.
[34] L. Presta,et al. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.
[35] Hans Clevers,et al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models , 2017, Cell Death & Differentiation.
[36] W. Delano. The PyMOL Molecular Graphics System , 2002 .